View all the latest information in graft-versus-host disease, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Is DPP-4 inhibition a feasible strategy for preventing acute GvHD?
Dipeptidyl peptidase 4 (DPP-4) is a transmembrane receptor (also called CD26), found on a variety of cell types and also present in...
When would you favor PTCy over CSA/MTX as GvHD prophylaxis after matched sibling donor HSCT?
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),...
Should omidubicel become SOC for umbilical cord blood transplantation?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to...
Editorial theme | Using a stem cell source as prophylaxis for cGvHD
Peripheral blood stem cells (PBSC) have become the predominant source of cells for hematopoietic stem cell transplantation (HSCT)...
Updated results from REACH2: Ruxolitinib for steroid-refractory acute GvHD
As previously reported on the GvHD Hub, the initial data from the phase III REACH2 trial uncovered the potential benefit of...
REACH2 study: What is the risk of losing response to ruxolitinib over time?
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub...
FDA grants orphan drug designation to axatilimab for the treatment of chronic GvHD
Axatilimab, an anti-colony stimulating factor 1 receptor monoclonal antibody for the treatment of chronic...
GRAVITAS-119: A phase I trial of itacitinib plus calcineurin inhibitor-based regimens for GvHD prophylaxis
Despite prophylactic measures, graft-versus-host disease (GvHD) remains a serious...
Mesenchymal stromal cells
Chemokine receptor antagonists
Fecal microbiota transplant
Nuclear receptor agonists